Calcagno Research and Development — Gresham, Oregon

Calcagno Research and Development is a clinical research site located in Gresham, Oregon, United States 97030.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Calcagno Research and Development has participated in 3 clinical trials.

Therapeutic areas: Dermatitis, Atopic, Atopic Dermatitis.

Sponsors: Novartis, MEDA Pharma GmbH & Co. KG, Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Gresham

Browse all research sites in Oregon · View every site in Gresham

• Oregon Health and Science University - CHO Gresham
• Legacy Mount Hood Medical Center
• Cyn3rgy Research
• GSK Investigational Site
• Research Site
• Cyn3Rgy Research-Clinedge-Ppds
• Cyn3rgy Research Center
• OHSU Knight Cancer Institute, Gresham
• Arcutis Clinical Site 17
• CIL #237
• Forest Investigative Site 053

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Calcagno Research and Development?

Calcagno Research and Development has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Calcagno Research and Development conducted?

Calcagno Research and Development has 3 clinical trials on record. Their work covers Dermatitis, Atopic, Atopic Dermatitis.

Is Calcagno Research and Development accredited by Crixeo Clinical Trials?

Calcagno Research and Development has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Calcagno Research and Development?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.